✦ LIBER ✦

Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma

✍ Scribed by Miki Tongu; Nanae Harashima; Takaya Yamada; Takayuki Harada; Mamoru Harada

Book ID: 105967706
Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 511 KB
Volume: 59
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-009-0797-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Postoperative Adjuvant Cisplatin, Doxoru

Postoperative Adjuvant Cisplatin, Doxorubicin, and Cyclophosphamide (PAC) Chemotherapy in Women with High-Risk Endometrial Carcinoma

✍ Thomas W. Burke; David M. Gershenson; Mitchell Morris; C.Allen Stringer; Charles 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 229 KB

Correlation between HER-2 expression and

Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma

✍ Fan Zhang; Ying Yang; Terry Smith; Shu-Wan Kau; Judy M. McConathy; Francisco J. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine whether HER‐2 overexpression is associated with improved response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, cyclophosphamide (FAC) in patients with breast carcinoma. ## METHODS Ninety‐seven patients with S

A prospective, randomized phase III tria

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

✍ Cesar Blajman; L. Balbiani; J. Block; F. Coppola; R. Chacon; L. Fein; S. Bonicat 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w

Adjuvant doxorubicin and cyclophosphamid

Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma : Results of a randomized controlled trial

✍ Soo-Mee Bang; Dae Seog Heo; Ki Hyeong Lee; Jae Ho Byun; Heung Moon Chang; Dong-Y 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

Low-dose mitomycin and weekly low-dose d

Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil

✍ Mariantonietta Colozza; Maurizio Tonato; Fausto Grignani; Stephen Davis 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel